AcelRx Baffled By Zalviso Trial Request On Opioid Dispensing Problems

FDA asked for clinical study before reviewing data AcelRx generated after previous ‘complete response,’ CEO King said.

AcelRx Pharmaceuticals Inc. is having a hard time explaining FDA’s request for a new clinical trial of its patient-activated acute pain drug/device system Zalviso.

Zalviso contains a novel, sublingual formulation of the opioid sufentanil for use in the hospital setting after surgery. With a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D